Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label extension and transition study of ocrelizumab for multiple sclerosis
MOH_2022-06-02_011833Phase 3Active, not recruiting
- Sponsor
- Roche
- Start
- May 2022
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of ocrelizumab in multiple sclerosis (MS) and primary progressive multiple sclerosis (PPMS), sponsored by Roche. Primary endpoint: Long-term safety of ocrelizumab. Started May 2022; status: active, not recruiting.
02
Drugs
ocrelizumab
03
Conditions
multiple sclerosis (MS)primary progressive multiple sclerosis (PPMS)
Beyond the preview
Go deeper on MOH_2022-06-02_011833.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2022-06-02_011833.